RNA Transfection Kit Primary Immune Cells

Satreda LNP2008

Transforming Primary Immune Cell Transfection

The Satreda LNP2008 kit represents a breakthrough in the delivery of RNA to primary immune cells, one of the most challenging cell types for genetic manipulation. Traditional methods often result in low transfection efficiency and high cytotoxicity, severely limiting the scope of immunological research and therapeutic development. LNP2008 overcomes these obstacles with next-generation LNP design, tailored specifically for primary immune cells, enabling safe, efficient, and reproducible RNA transfection.

Dynamic Membrane Fusion Technology

At the heart of LNP2008’s performance is dynamic membrane fusion technology, which enables the nanoparticles to efficiently merge with cellular membranes and deliver RNA into the cytoplasm. This unique mechanism minimizes cellular stress and maximizes RNA uptake, ensuring reliable expression in even the most difficult-to-transfect immune cells.

pH-Responsive Ionizable Lipids for Precision Release

LNP2008 is equipped with novel pH-responsive ionizable lipids that sense the microenvironment inside endosomes and release RNA precisely where it is needed. This mechanism enhances intracellular delivery while preventing premature release, thereby protecting the RNA cargo and ensuring maximum biological activity.

Safe, Non-Viral, and Research-Ready

Unlike viral vectors, LNP2008 is non-viral, biodegradable, and ethanol-free, ensuring ultra-low cytotoxicity and high biocompatibility. This makes it suitable not only for high-impact research but also for preclinical studies where safety and reproducibility are paramount. The ready-to-use formulation simplifies experimental workflows, requiring no specialized equipment or long preparation times.

Proven Efficiency in Primary T Cells

Validated in human primary T cells, LNP2008 demonstrates visible RNA expression within 24 hours, far surpassing conventional methods. This rapid, efficient performance opens new possibilities for studies involving CAR-T therapy development, dendritic cell vaccine research, and broader immunotherapy applications.

Enabling the Future of Immunotherapy

By combining dynamic delivery, precision release, and unrivaled safety, LNP2008 establishes a new technological benchmark for primary immune cell transfection. It provides researchers with a powerful and reliable platform for advancing next-generation immunotherapies, vaccines, and precision medicine solutions.